Paper34835459
Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.
Ezquerra-Aznárez JM and 2 others. Microorganisms, 2021. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs. Papers, record 34835459. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34835459
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| FPU18/03873 to JMEA | Ministerio de Universidades (Spain) | PubMed | ||
| Capes-PrInt Program, - Financing Code 001 to PEAS | Coordenação de Aperfeicoamento de Pessoal de Nível Superior | PubMed |
Source PubMed
References101
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29649664 | Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48. | Int J Parasitol Drugs Drug Resist | 2018 | https://conductscience.org/library/papers/29649664 | PubMed |
| 3 | 22589723 | Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. | PLoS Pathog | 2012 | https://conductscience.org/library/papers/22589723 | PubMed |
| 4 | 464563 | Avermectins, new family of potent anthelmintic agents: efficacy of the B1a component. | Antimicrob Agents Chemother | 1979 | https://conductscience.org/library/papers/464563 | PubMed |
| 5 | 28167557 | Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28167557 | PubMed |
| 6 | 23507275 | Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23507275 | PubMed |
| 7 | 22877082 | Review of pyronaridine anti-malarial properties and product characteristics. | Malar J | 2012 | https://conductscience.org/library/papers/22877082 | PubMed |
| 8 | 10707260 | Antituberculosis activity of certain antifungal and antihelmintic drugs. | Tuber Lung Dis | 1999 | https://conductscience.org/library/papers/10707260 | PubMed |
| 9 | 21393225 | Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. | J Antimicrob Chemother | 2011 | https://conductscience.org/library/papers/21393225 | PubMed |
| 10 | 30205975 | The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. | Tuberculosis (Edinb) | 2018 | https://conductscience.org/library/papers/30205975 | PubMed |
| 11 | 25079790 | Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. | PLoS Negl Trop Dis | 2014 | https://conductscience.org/library/papers/25079790 | PubMed |
| 12 | 18159536 | Where are all the new antibiotics? The new antibiotic paradox. | Can J Infect Dis Med Microbiol | 2005 | https://conductscience.org/library/papers/18159536 | PubMed |
| 13 | 6893469 | Ivermectin, a new broad-spectrum antiparasitic agent. | J Med Chem | 1980 | https://conductscience.org/library/papers/6893469 | PubMed |
| 14 | 12019076 | Mefloquine and new related compounds target the F(0) complex of the F(0)F(1) H(+)-ATPase of Streptococcus pneumoniae. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12019076 | PubMed |
| 15 | 27338184 | Benzimidazole resistance in helminths: From problem to diagnosis. | Acta Trop | 2016 | https://conductscience.org/library/papers/27338184 | PubMed |
| 16 | 16143463 | In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. | FEMS Microbiol Lett | 2005 | https://conductscience.org/library/papers/16143463 | PubMed |
| 17 | 18491971 | Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. | J Infect Dis | 2008 | https://conductscience.org/library/papers/18491971 | PubMed |
| 18 | 29987141 | Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29987141 | PubMed |
| 19 | 29603892 | Niclosamide, a Drug with Many (Re)purposes. | ChemMedChem | 2018 | https://conductscience.org/library/papers/29603892 | PubMed |
| 20 | 24736743 | A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis. | PLoS One | 2014 | https://conductscience.org/library/papers/24736743 | PubMed |
| 21 | 16569295 | Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. | Parasitology | 2005 | https://conductscience.org/library/papers/16569295 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37110480 | Mycobacterium tuberculosis Infection: Control and Treatment. | Microorganisms | 2023 | https://conductscience.org/library/papers/37110480 | PubMed |
| 37020538 | Immunomodulation resulting of helminth infection could be an opportunity for immunization against tuberculosis and mucosal pathogens. | Front Immunol | 2023 | https://conductscience.org/library/papers/37020538 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ABCG2 | 9429 | PubTator's text mining | https://conductscience.org/library/genes/9429 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34835459
GET https://conductscience.org/api/papers/v1/34835459/references?page=2